ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.82
+0.32 (+2.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.50
Open12.70
Bid12.85 x 2200
Ask12.85 x 3200
Day's Range12.45 - 13.09
52 Week Range6.75 - 15.00
Volume2029111
Avg. Volume921,158
Market Cap709M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    Schizophrenia: Lumateperone’s clinical profile including its motor and cardiometabolic profile was showcased in pooled analyses of randomized short-term clinical trials and a long-term safety study. Lumateperone and the Metabolic Syndrome (MetSy): Post-hoc analyses from short-term placebo-controlled studies in schizophrenia on MetSy in patients treated with lumateperone and in patients treated with risperidone were presented.

  • GlobeNewswire

    Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) to be held in Hollywood, FL, December 8-11, 2019. Intra-Cellular Therapies will be presenting the following posters and presentations at ACNP, which will include results from Study 404, a Phase 3 clinical trial evaluating lumateperone for the treatment of bipolar depression, as well as new data from the schizophrenia clinical program including the long-term safety study. Lumateperone is a novel investigational drug currently under review by the FDA as a potential treatment for adults with schizophrenia.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 05, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswire

    Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 5, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2019. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2019 Cantor Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

    Intra-Cellular Therapies, Inc. (ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) in Study ITI-214-104 (Study ‘104), a proof-of-mechanism, translational medicine study of ITI-214, a novel phosphodiesterase-1 (PDE1) inhibitor, in patients with chronic heart failure.  Clinical conduct of the third and last cohort, 90 mg, is now ongoing following review of safety and tolerability data from the 30 mg dose cohort, where no safety concerns were identified. Initiation of Study 104 followed findings that ITI-214 improved cardiac output through a different mechanism of action than available heart failure therapies.  These findings in a preclinical model of heart failure were published by researchers at Johns Hopkins University and ITCI scientists in the journal Circulation.  Currently available heart failure drugs that strengthen heart contractions, such as the PDE3 inhibitors (amrinone and milrinone) and ß-adrenergic agonists (dobutamine), increase calcium entry into cardiac muscle cells and have potentially dangerous complications, such as irregular heartbeats.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not have plans to schedule an Advisory Committee meeting in connection with its review of the Company’s New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The lumateperone Prescription Drug User Fee Act (PDUFA) goal date is December 27, 2019.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    NEW YORK, Aug. 07, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 39th  Annual Growth Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA

    Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophreniaLumateperone PDUFA goal date.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The Company has a meeting scheduled with the FDA shortly and will provide an update following the meeting.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression

    Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p

  • GlobeNewswire

    Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Karen Patruno Sheehy, Esq. In prior roles, Karen led compliance functions at Mallincrodt as Senior Vice President, Chief Compliance Officer and at Sanofi as Vice President, Head, North America Compliance.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at JMP Securities Life Sciences Conferences Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the  U.S. Food and Drug Administration (FDA) has announced a Psychopharmacologic Drugs Advisory Committee meeting to be held on July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone with the proposed indication of treatment of schizophrenia in adults. Lumateperone is a novel investigational drug with an NDA currently under review by FDA as a treatment of schizophrenia in adults.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at Jefferies 2019 Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at Jefferies 2019 Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2019 RBC Capital Markets Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the presentation of posters highlighting the lumateperone program in schizophrenia at the 2019 American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18-22, 2019. Lumateperone is a novel investigational drug currently under review by the FDA as a potential treatment for adults with schizophrenia.

  • GlobeNewswire

    Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    NEW YORK, May 08, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • GlobeNewswire

    Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, May 8, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2019. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research revolutionized our understanding of the biochemistry of the brain. Dr. Greengard’s Nobel prize-winning work in intracellular signaling was the foundation of the company’s formation in 2002. “We are deeply saddened by the news of Paul’s passing.

  • GlobeNewswire

    Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone, an investigational drug, in patients with stable symptoms of schizophrenia. Results were also presented on the improvements in symptoms of depression in patients with moderate to severe co-morbid depression.  The data were presented at the 2019 Congress of the Schizophrenia International Research Society (SIRS), which was held in Orlando, Florida, April 10-14, 2019. “Schizophrenia is a multidimensional illness with high rates of comorbidities, including depressive symptoms.

  • GlobeNewswire

    Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market Access, Policy and Government Affairs.  Mr. Bardi has over 30 years of biopharmaceutical and health system industry experience with a strong track record of innovation and building high-performing Market Access, Government Affairs, and Digital Medicine business development teams and capabilities across many disease areas.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 39th Annual Healthcare Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    NEW YORK, Feb. 27, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.